SCHEMBL19093292

SCHEMBL19093292

CCOC(=O)C12CC1/C=C/CCCCNC(=O)C1CC(Oc3cc(-c4ccccc4)nc4cc(OC)ccc34)CC1C(=O)N2C

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CTSB P07858 1/20 0.59
▸ CTSS P25774 1/20 0.38
▸ KDM4E B2RXH2 1/20 0.36
▸ ALDH1A1 P00352 1/20 0.36
▸ SMN1; SMN2 Q16637 1/20 0.36
▸ TACR3 P29371 5/20 0.33
▸ ADAM17 P78536 1/20 0.33
▸ TDP1 Q9NUW8 2/20 0.32
▸ NPC1 O15118 1/20 0.32
▸ MITF O75030 1/20 0.32
▸ MAPT P10636 1/20 0.32
▸ HTT P42858 1/20 0.32
▸ RAB9A P51151 1/20 0.32
▸ PAX8 Q06710 1/20 0.32
▸ HTR3E A5X5Y0 1/20 0.31
▸ HTR3B O95264 1/20 0.31
▸ HTR3A P46098 1/20 0.31
▸ HTR3D Q70Z44 1/20 0.31
▸ HTR3C Q8WXA8 1/20 0.31
▸ ADRB3 P13945 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19093294 1.00 CTSB (0.59) CTSBCTSSKDM4EALDH1A1SMN1; SMN2
SCHEMBL3049467 0.88 CTSB (0.62) CTSBCTSSKDM4EALDH1A1SMN1; SMN2
SCHEMBL8286271 0.88 CTSB (0.62) CTSBCTSSKDM4EALDH1A1SMN1; SMN2
SCHEMBL3049462 0.88 CTSB (0.62) CTSBCTSSKDM4EALDH1A1SMN1; SMN2
SCHEMBL8286783 0.83 CTSB (0.77) CTSBCTSSKDM4EALDH1A1SMN1; SMN2
SCHEMBL3039922 0.83 CTSB (0.77) CTSBCTSSKDM4EALDH1A1SMN1; SMN2
SCHEMBL3039916 0.83 CTSB (0.77) CTSBCTSSKDM4EALDH1A1SMN1; SMN2
SCHEMBL3049795 0.82 CTSB (0.66) CTSBCTSSKDM4EALDH1A1SMN1; SMN2
SCHEMBL8285112 0.82 CTSB (0.66) CTSBCTSSKDM4EALDH1A1SMN1; SMN2
SCHEMBL3049806 0.82 CTSB (0.66) CTSBCTSSKDM4EALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10172846-B2 HCV NS-3 serine protease inhibitors MEDIVIR AB (SE) 2019-01-08 — — US disclosed
US-20170196849-A1 HCV NS-3 SERINE PROTEASE INHIBITORS MEDIVIR AB (SE) 2017-07-13 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170196849-A1 HCV NS-3 SERINE PROTEASE INHIBITORS HPN, CPN1, PRSS1 CTSB 168/4885CTSS 89/4885KDM4E 4633/4885
US-10172846-B2 HCV NS-3 serine protease inhibitors HPN, CPN1, PRSS1 CTSB 168/4885CTSS 89/4885KDM4E 4633/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback